Flunisolide is an inhaled corticosteroid used as a prophylactic therapy in the maintenance treatment of asthma. Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions.
- Mechanism
- Curator reviewed
Flunisolide is a glucocorticoid receptor agonist. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Flunisolide binds to plasma transcortin, and it becomes active when it is not bound to transcortin.
- Primary indication
- For the maintenance treatment of asthma as a prophylactic therapy.Curator reviewed · 2 structured indications
- Formula / weight
- C24H31FO6 · 434.4977 g/mol (avg)
- First approval
- Canada, 1997 · United States, 1995
Resolves to
XSFJVAJPIHIPKU-XWCQMRHXSA-NSMILES[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COWhat you can answer from here — as of September 12, 2026
Which drugs share a target with Flunisolide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account